In conclusion, SGLT2 inhibitors provide cardiovascular and renal protection in type 2 diabetes mellitus patients, with suppression of sympathetic overactivity being one of the less understood but critical processes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.